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Abstract
Background: Cigarette smoking cannot fully explain the epidemiologic characteristics of chronic obstructive
pulmonary disease (COPD) in women, particularly for those who rarely smoke, but COPD risk is not less than men.
The aim of our study is to investigate the relationship between second-hand smoke (SHS) exposure and chronic
bronchitis in Taiwanese women.
Methods: We used Taiwan’s National Health Insurance Bureau claims data in 1999, and cross-checked using criteria
set by the American Thoracic Society; there were 33 women with chronic bronchitis, 182 with probable chronic
bronchitis, and 205 with no chronic bronchitis during our interview time between 2000 and 2005. We measured
second-hand smoke (SHS) exposure by self-reported measures (household users and duration of exposure), and
validated this by measuring urinary cotinine levels of a subset subjects. Classification of chronic bronchitis was also
based on spirometry defined according to the GOLD guidelines to get the severity of COPD.
Results: Women who smoked and women who had been exposed to a lifetime of SHS were 24.81-fold (95% CI:
5.78-106.38) and 3.65-fold (95% CI: 1.19-11.26) more likely to have chronic bronchitis, respectively, than those who
had not been exposed to SHS. In addition, there was a significant increasing trend between the severity of COPD
and exposure years of SHS (p < 0.01). The population attributable risk percentages of chronic bronchitis for
smokers and those exposed to SHS were 23.2 and 47.3% respectively.
Conclusions: These findings indicate that, besides cigarette smoking, exposure to SHS is a major risk factor for
chronic bronchitis in Taiwanese women.
Background
Chronic obstructive pulmonary disease (COPD), a
chronically progressive disease that includes chronic
bronchitis and emphysema [1], remains a major public
health problem and its prevalence and mortality are
increasing throughout the world [2-4]. In Taiwan,
C O P Dh a sr a n k e ds t a b l ya st h e1 0
th-12
th leading cause
of death since 2000. However, until now, COPD is still
the second most prevalent reason for visits to physicians
(8,135 and 6,408 per 100,000 persons in 2000 and 2006
respectively) and its medical care cost is also highest at
the 6
th rank [5] among leading causes of death. Further-
more, COPD is estimated to be the third most common
cause of death worldwide by 2020 [3]. Since no effective
treatment exists to block its progress [6] and taking into
account the economic burden of medical care resources
worldwide [7], prevention of COPD is critical to public
health.
Cigarette smoking is a well-known risk factor for
COPD in men [8]. The prevalence of cigarette smoking
in Taiwanese men is very high (55-60%), but low among
Taiwanese women (3-4%) from 1974 to date [9-11], sug-
gesting that potentially, a large number of non-smoking
Taiwanese women are exposed to second-hand smoke
(SHS). According to a government report, COPD ranked
as both the 12
th leading cause of death in men (5.9 per
100,000) and women (3.6 per 100,000) in 2008 [5]. Liu
and his colleagues also found 81% deaths of COPD in
never smokers in rural Chinese women with the same
low smoking rates as Taiwanese women [12]. All these
results suggest that cigarette smoking per se cannot
fully explain the epidemiologic characteristics of COPD
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smoke but have COPD risk not less than men.
Similar to cigarette smoke, besides carcinogenic com-
ponents, SHS contains many potent pulmonary irritants
[13], all known to cause inflammatory or irritant reac-
tions in the airways leading to respiratory symptoms or
lung function impairment [14,15]. Recently, Woodruff
and his colleagues provided a biological link between
S H Se x p o s u r ea n dt h ed e v e l opment of inflammatory
processes and even COPD in mice experiments due to
alveolar macrophage recruitment and activation [16]. In
2002, Jaakkola and Jaakkola reported that there was still
limited evidence of SHS effect on the risk of COPD
[14]. Although a series of studies was published subse-
quently [17-28], the findings were conflicting. Thus, we
conducted a health-care-based case-control study to
investigate the association between SHS exposure and
risk for chronic bronchitis in Taiwanese women, whose
smoking rate was very low.
Methods
Study area and population
Our study setting was Kaohsiung City, a harbor city
located on the southwestern coast of Taiwan (153.6 km
2
and has 11 administrative districts), belonging administra-
tively to Taiwan’s National Health Insurance Program
Kao-Ping District, which administers to 3,234,941 persons
in Taiwan’s Kaohsiung and Pingtung areas in 1999. During
that year, 1,065,624 Kaohsiung City residents had applied
for health insurance compensation. Ninety-six percent of
Taiwan’s citizens are enrolled in Taiwan’s National Health
Insurance Scheme, and 93% of the physicians there have
contracts with the National Health Insurance Bureau [29],
making its database nationally representative.
According to the Kao-Ping District insurance database
for 1999, a total of 221,965 female Kaohsiung residents
40 years of age or older made health insurance claims.
Kaohsiung municipal records confirmed that they had
lived in the city for 5 years or more. These women were
defined as study cases if they had received a diagnosis of
definite or suspected chronic bronchitis (ICD-9 code:
491) at least twice in 1999. Those who had sought med-
ical attention for traffic accidents (ICD-9 code: E800-
E848) or acute gastroenteritis (ICD-9 code: 008.8; 009.1;
558.3; 558.9) in the same year and had never been diag-
nosed as having chronic bronchitis were used as study
controls. We excluded both study cases and controls if
they had been diagnosed with other pulmonary-asso-
ciated diseases, including asthma (ICD-9 code: 493), pul-
monary tuberculosis (ICD-9 code: 011.9 or 010-018),
bronchiectasis (ICD-9 code: 494), fibrotic cyst (ICD-9
code: 277), pulmonary tumor (ICD-9 code:162), emphy-
sema (ICD-9 code: 492), extrinsic allergic alveolitis
(ICD-9 code: 495), or chronic airway obstruction, not
elsewhere classified (ICD-9 code: 496). We were left
with 1,846 study cases and 4,624 controls (Additional
file 1).
Between June, 2000 and March, 2005, about one-third
of the study cases (n = 622) were randomly selected,
interviewed and administered pulmonary function tests
in their homes. Once a study case was successfully
recruited, interviewed and administered a pulmonary
function test, we found one study control age-matched to
within 3 years. The matched control was chosen from
the same administrative area to adjust for the possible
influence from external environmental hazards such as
air pollution from large factories or traffic. After exclud-
ing those who refused to participate or those we could
not locate, etc., we had 210 study cases and 210 controls
successfully complete the interview and pulmonary func-
tion tests, making a response rate of 67.3% and 68.4%
respectively. The average age (±SD) (years) of responders
(n = 210) and non-responder study cases were 64.6 ± 9.6
and 63.2 ± 10.8, which was not significantly different
(p = 0.11); of responders and non-responder study con-
trols were 64.6 ± 9.7 and 64.7 ± 11.2, which was also not
significantly different (p = 0.91). This study was approved
by IRB at Kaohsiung Medical University, and all potential
subjects signed informed consent forms.
SHS exposure measurement
Questionnaire
Epidemiologic data was obtained by trained interviewers
who conducted personal interviews in the homes of our
study subjects. The questionnaire, which was a modified
version of the American Thoracic Society Division of
Lung Disease Respiratory Symptom Questionnaire [1],
included the demographic characteristics and socioeco-
nomic status of the participants and questions about the
presence of chronic bronchitis symptoms, family history
of respiratory diseases, and exposure to airborne house-
hold chemicals, including cigarette smoking, SHS, cook-
ing oil fumes, and incense burning. The interview lasted
around 30 minutes.
Detailed information about cigarette smoking and SHS
exposure was collected concerning their three age peri-
ods: childhood (≤ 20 years) exposure at home, early
adult life (20-40 years) and late adult life (> 40 years)
exposure at home and the workplace. Smokers were
defined as those who responded “Yes” to the question,
“Have you ever smoked, on average, more than one
cigarette per day for at least one year?” during any of
their three age periods. Ex-smokers were defined as
those who had quit at least one year during any of their
three age periods; we categorized them as smokers due
to the small sample size.
If the study subject was not a smoker, two separate
self-reported measures were used for SHS exposure
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Page 2 of 10assessment. The first measure was based on household’s
or co-workers’ cigarette smoke used separately, and sec-
ond-hand smokers were defined as those who responded
“Yes” to the question, “Have you ever lived with a smo-
ker or co-workers smoking nearby while indoors work-
ing and, on average, been exposed face-to-face to more
than one cigarette per day for at least one year?” during
a n yo ft h et h r e ea g ep e r i o d s .T h es e c o n dm e a s u r ew a s
based on duration of SHS exposure in lifetime exposure
with a series of detailed questions including what year
exposure started and what year exposure ceased or how
long they had been exposed (in years) to SHS. We cal-
culated lifetime cumulative SHS exposure by summing
the number of years the second-hand smokers reported
exposure to smokers in the three age periods at home
and work separately and combined. However, only 33%
o fw o m e ni no u rs t u d yh a dw o r k e dd u r i n gt h e i re a r l y
adult life and most of them became housewives during
their later adult life, so the level of cumulative exposure
was categorized into < 32 years and ≥ 32 years based on
median cumulative SHS exposure of years at home only.
Subjects who were neither smokers nor second-hand
smokers were considered as non-smokers.
Validation of SHS exposure
To verify the participant’s response that she was a cigar-
ette smoker or had been exposed to SHS exposure
reported on the questionnaire, we randomly selected 4
smokers, 23 second-hand smokers, and 44 non-smokers
to provide one-spot urine specimens so that we could
measure cotinine levels. Urinary cotinine was extracted
by a liquid-liquid extraction method and measured by
liquid chromatography tandem mass spectrometry (LC/
MS/MS) equipped with a triple-quadruple mass spectro-
meter and TurboIonSpray™ (API 3000™, Applied Biosys-
tems, Foster City, CA, USA) [30]. The urine specimen
was co-spiked with cotinine-d3 as an internal standard.
The detection limit for cotinine was 0.07 ng/ml. Urinary
creatinine was measured by spectrophotometer (U-2000,
Hitachi, Tokyo, Japan) with a wavelength set at 520 mm.
Since cotinine can only be used to test recent expo-
sure to cigarette smoke, we could only use it to confirm
the questions regarding the smoking of cigarettes and
exposure to cigarettes in the past three days prior to the
interview, when the urine specimens were collected. The
mean urinary cotinine levels in the four active smokers
were 0.79 ± 0.13 mg/g creatinine, significantly higher
than that found for the 23 second-hand smokers (0.006
± 0.006 mg/g creatinine) and 44 non-smokers (0.002 ±
0.002 mg/g creatinine) (both p < 0.01). The urinary coti-
nine levels in the second-hand smokers were also signif-
icantly higher than those in the non-smokers (p <0 . 0 1 )
(Additional file 2). Nineteen of 23 second-hand smokers
had information about the number of cigarettes they
had been exposed to in the past three days prior to the
interview. We found a high correlation between the
number of cigarettes they reported being exposed to
and the urinary cotinine levels (Spearman correlation
coefficients, r = 0.55, p = 0.02, n = 19) (Figure 1), con-
firming the validity of our SHS questionnaire.
Outcome measurements
Pulmonary function test
Pulmonary function measurement is the most important
indicator of respiratory impairment in COPD [6]. Thus,
after the face-to-face interview in the participant’s
home, the interviewers asked the participant to perform
a pulmonary function test using a portable spirometer
(Micro Direct Inc. MS03 MicroPlus, Rochester, England)
for our community survey, which has been used by
another study [31]. Spirometers were calibrated daily
using a 3-L syringe. Forced expiratory volume in 1
st sec-
ond (FEV1), forced vital capacity (FVC) and FEV1/FVC
were recorded [1]. Each participant performed the pul-
monary function tests at least three times. The highest
of the scores were recorded. None of the participants
had smoked, eaten, or used any bronchodilators within
one hour prior to performing the pulmonary function
tests. Allpulmonary function tests followed the guideli-
nesof the American Thoracic Society (ATS) [1]. To cal-
culate the percent predicted values for lung function, we
used predictive equations derived from Baldwin’sf o r -
mula for FVC and Berglund’s formula for FEV1 [32,33].
Chronic bronchitis related health status
We used two disease classification systems to categorize
chronic bronchitis-related health status in our data ana-
lysis (Additional file 1). First, we classified all study sub-
jects into three disease groups based on (1) a physician’s
Figure 1 Correlation between the urinary cotinine levels (mg/g
creatinine) and the number of cigarettes they reported
themselves as being exposed to SHS during the 3 days leading
up to the collection of urine specimens. (Spearman correlation
coefficients, r = 0.55, p = 0.02, n = 19)
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1999 and on (2) the ATS criteria for chronic bronchitis
(the presence of cough and/or sputum production dur-
ing the majority of days for at least three consecutive
months in the previous two or more successive years)
[1]. The three disease groups included 33 chronic bron-
chitis sufferers (those who satisfied both criteria), 182
probably with chronic bronchitis (those who satisfied
any one of criteria), and 205 with no chronic bronchitis
(those who satisfied neither set of criteria).
Second, using pulmonary function test data (FEV1 and
FVC), we categorized COPD into various levels of sever-
ity as described previously by the National Heart, Lung,
and Blood Institute/World Health Organization GOLD
criteria (Stages 0-IV) [6]. We classified 230 subjects as
being Stage 0, meaning that lung function was normal
(FEV1/FVC ≥ 70% and FEV1 ≥ 80% predicted), 24 as
being Stage I, meaning that airflow was mildly limited
(FEV1/FVC<70% and FEV1 ≥ 80% predicted), 41 as being
Stage II, meaning that airflow was increasingly limited
(FEV1/FVC<70% and 50% ≤ FEV1<80% predicted), 13 as
being Stage III (FEV1/FVC<70% and 30% ≤ FEV1<50%
predicted) and finally 4 as being Stage IV (FEV1/
FVC<70% and FEV1<30% predicted), meaning that air
flow was severely limited. We combined the Stage II to
Stage IV as one group due to the small sample size. For
the same reason, we moved those pulmonary function
test scores ranging between FEV1/FVC ≥ 70% and 30% ≤
FEV1 < 80% into Stage I group. After combining these
groups, 230 could be classified as being Stage 0 (renamed
as No COPD), 129 as being Stage I (renamed as Mild
COPD) and 58 as being Stage II-IV (renamed as Moder-
ate COPD). Three subjects were excluded because of no
pulmonary function test information.
Statistical Analysis
Paired t-statistics and univariate conditional logistic
regression were first used to compare the demographics
of the 210 study cases and their age- and district-
matched controls. After we further crosschecked using
criteria set by the ATS into three disease groups and
severity of COPD, c
2 and Fisher’s exact tests, or ANOVA
statistics, when appropriate, were used to compare the
differences of different variables. We used polytomous
logistic regressions to elucidate the association between
cigarette smoking (yes vs. no) and SHS exposure (yes vs.
no), including cumulative SHS exposure categories (<32
and ≥ 32 years), and health status outcomes (based on
physician diagnosis and ATS criteria, and spirometry by
GOLD criteria) in three age periods and then combined
these into a lifetime period, adjusting for age, height, edu-
cational level, cooking status, burning incense, and tea
consumption. Statistical significance of trend in the
adjusted odds ratios (AORs) across cigarette smoking
and SHS exposure and different health status outcomes
were calculated by categorizing variables and treating
scored variables as continuous. Multiple linear regres-
sions were used to investigate the relationship between
the same individual variables and pulmonary function
(FEV1,F V Ca n dF E V 1/FVC). In addition, we calculated
the population attributable risk percentages (PAR%) of
cigarette smoking and SHS exposure for chronic bronchi-
tis and probable chronic bronchitis, also for severity of
COPD [34]. The data was analyzed using the SAS statisti-
cal package; all p-values were two-sided.
Results
Characteristics of subjects on different health outcomes
Firstly, we had 210 study cases and 210 age- and dis-
trict-matched controls (Additional file 1). There were no
significant differences in the age, height, weight, educa-
tion levels, and cigarette smoking between the two
groups (data not shown). Only 3% of women had ever
worked in a restaurant. The mean FEV1 levels (L) in the
study cases and controls were 1.48 ± 0.42 and 1.64 ±
0.49 (p < 0.01), and the mean FVC levels (L) were 1.90
± 0.53 and 2.00 ± 0.61 (p = 0.02) respectively.
Table 1 shows the demographic distributions of three
disease groups, chronic bronchitis, probable chronic
bronchitis and no chronic bronchitis groups. Weight
and BMI were significantly different among these three
disease groups (p = 0.01). Those with chronic bronchitis
had significantly lower lung function in FEV1,F V Ca n d
FEV1/FVC than either of the other two groups. In addi-
tion, the smoking rate in the group of chronic bronchitis
was 24.2%, significantly higher than the other two
groups (5.8 and 3.9%, p < 0.01).
Impact of SHS exposure on health status based on
physician diagnosis and ATS criteria
As shown in Table 2, we analyzed the three disease
groups by whether or not they smoked or were exposed
to SHS, further categorized into less than 32 years and
more than 32 years exposure in their lifetime. Smokers
and second-hand smokers were 24.81-fold (95% CI:
5.78-106.38) and 3.65-fold (95% CI: 1.19-11.26) more
likely to have chronic bronchitis than the non-smokers.
In addition, those with SHS exposure under 32 years
had a significantly greater risk (AOR = 4.26, 95%CI:
1.29-14.09) of having chronic bronchitis than non-smo-
kers, though this was not found in those with SHS
exposure over 32 years (AOR = 3.02; 95%CI: 0.85-10.70)
due to small sample size. For probable chronic bronchi-
tis, we also noted a significant increasing trend of risk
by years of SHS exposure compared to those not
exposed to SHS (trend test, p = 0.01). The PAR% for
chronic bronchitis was 23.2% and 47.3% in smokers and
those exposed to SHS respectively.
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spirometry by GOLD criteria
Table 3 shows smokers and second-hand smokers were
6.49-fold (95% CI: 1.61-26.25) and 3.84-fold (95% CI:
1.72-8.60) more likely to have moderate COPD than the
non-smokers. In addition, those with SHS exposure
under 32 years (AOR = 3.31, 95%CI: 1.36-8.06) and over
32 years (AOR = 4.43, 95%CI: 1.85-10.60) had signifi-
cantly greater risks of having moderate COPD than non-
smokers. We also noted a significant increasing trend of
risk of having mild COPD and moderate COPD by years
of SHS exposure, compared to those not exposed to SHS
(trend test, p = 0.01 and < 0.01 respectively). Smokers,
making up a small percentage of our study population,
had a PAR% of 8.9% and 7.3% for mild COPD and mod-
erate COPD, whereas second-hand smokers, making up
62% of our study population, had a PAR% of 26.5% and
56.2% for mild and moderate COPD.
Impact of SHS exposure on pulmonary function status
Using FEV1, FVC or FEV1/FVC ratio as an outcome indi-
c a t o r ,w ef o u n dt h e r ew a sam o r es i g n i f i c a n tw o r s e n i n g
in mean FEV1 values in smokers (246 mL, p <0 . 0 1 )a n d
second-hand smokers (104 mL, p = 0.01) than in non-
smokers, after adjusting for other covariates (data not
s h o w n ) .I na d d i t i o n ,m e a nF E V 1 values significantly
decreased 113 mL (p = 0.01) and 95 mL (p = 0.04) in
subjects exposed to SHS ≥ 32 years and < 32 years
respectively, compared to those in non-smokers, after
adjusting for cigarette smoking and other covariates
(Table 4). Similar results were found when we used
FEV1/FVC ratio as an indicator (Table 4). No significant
Table 1 Demographic characteristics of chronic bronchitis, probable chronic bronchitis, and no chronic bronchitis
according to physician diagnosis and ATS criteria (n = 420)
a
Variables Chronic bronchitis
(n = 33)
Probable chronic bronchitis
(n = 182)
No chronic bronchitis
(n = 205)
p-value
Mean (SD)
Age (yrs) 65.2 (12.3) 64.6 (9.1) 64.5 (9.7) 0.94
Height (cm) 154.5 (4.3) 155.5 (5.7) 155.2 (4.8) 0.59
Weight (kg) 54.0 (10.0) 57.7 (7.5) 58.5 (7.5) 0.01
BMI 22.6 (3.9) 23.9 (3.0) 24.3 (3.1) 0.01
Pulmonary function test
FEV1 (L) 1.33 (0.52)
a 1.51 (0.40) 1.64 (0.48) <0.01
FVC (L) 1.74 (0.58)
a 1.94 (0.52) 2.00 (0.62) 0.05
FEV1/FVC (%) 76.1 (17.1)
a 78.9 (15.0) 83.8 (15.5) <0.01
N (%)
Education levels
≥ junior high school 5 (15.2) 32 (17.6) 34 (16.6) 0.67
primary school 16 (48.5) 93 (51.1) 117 (57.1)
illiteracy 12 (36.4) 57 (31.3) 54 (26.3)
Cigarette smoking
no 25 (75.8) 172 (94.5) 197 (96.1) <0.01
b
yes 8 (24.2) 10 (5.5) 8 (3.9)
Alcohol consumption
no 33 (100) 176 (96.7) 200 (97.6) 0.14
b
yes 0 6 (3.4) 5 (2.5)
Tea consumption
no 31 (93.9) 152 (83.5) 164 (80.0) 0.13
b
yes 2 (6.1) 30 (16.5) 41 (20.0)
Burning incense
no 14 (42.4) 81 (44.5) 89 (43.4) 0.96
yes 19 (57.6) 101 (55.5) 116 (56.6)
Cooking status
no 2 (6.1) 9 (5.0) 6 (2.9) 0.50
b
Yes 31 (93.9) 173 (95.1) 199 (97.1)
aThree subjects did not have complete lung function test information
bFisher’s exact test.
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measurements were observed (data not shown).
Discussion
Main findings of this study
This study indicates that, besides cigarette smoking,
SHS exposure significantly increases the risk of
chronic bronchitis in non-smoking Taiwanese women
by using different outcome indicators, including physi-
cian-diagnosis/ATS criteria, the severity of COPD [6]
and pulmonary function (FEV1 or FEV1/FVC ratio)
impairment. We also used the urinary cotinine levels for
the validation of self-report to SHS exposure. These
results were also seen when exposure assessment was
based on duration of SHS exposure at home, rather than
household-reported cigarette smoke use alone.
Our results of increased risk of chronic bronchitis
with SHS exposure in women concur with some pre-
vious studies [24,26,27]. However, some of the studies
have shown mixed results (Additional file 3). The defi-
nitions of COPD/chronic bronchitis may be one of the
reasons. We used two sets of disease classification of
chronic bronchitis concurrently, to reduce the possibi-
lity of misclassification of our surveyed subjects and
illustrate the effect of chronicb r o n c h i t i sm o r ec l e a r l y .
One case-control study conducted by Kalandidi and
his colleagues found that women married to smokers
and exposed to ≤ 1 pack/day were at 2.5 times (95%
Table 2 Relationships between cigarette smoking and SHS exposure in lifetime status and chronic bronchitis and
probable chronic bronchitis according to physician diagnosis and ATS criteria.
Variables No chronic bronchitis
(n = 205)
Probable chronic bronchitis
(n = 182)
Chronic bronchitis (n = 33)
N (%) N (%) AOR (95%CI)
a PAR (%) N (%) AOR (95%CI)
a PAR (%)
Cigarette smoking/SHS status
Non-smoker 76 (37.1) 52 (28.6) 1 4 (12.1) 1
Second-hand smoker 121 (59.0) 120 (65.9) 1.57 (1.00-2.45) 23.8 21 (63.6) 3.65 (1.19-11.26)
c 47.3
Smoker 8 (3.9) 10 (5.5) 1.99 (0.72-5.48) 2.6 8 (24.2) 24.81 (5.78-106.38)
c 23.2
Cigarette smoking and
cumulative SHS exposure (year)
Non-smoker 76 (37.1) 52 (28.6) 1 4 (12.1) 1
Second-hand smoker
1< SHS < 32 67 (32.7) 53 (29.1) 1.24 (0.74-2.10) 13 (39.4) 4.26 (1.29-14.09)
c
SHS ≥ 32 54 (26.3) 67 (36.8) 1.93 (1.16-3.23)
b 8 (24.2) 3.02 (0.85-10.70)
b,c
Smoker 8 (3.9) 10 (5.5) 2.00 (0.73-5.51) 8 (24.2) 24.74 (5.77-106.15)
aAOR: Adjusting for age, secondhand smoke status, height, education level, cooking status, burning incense and tea consumption.
bTrend test from non-SHS, 1<SHS<32, to SHS ≧ 32 years in probable chronic bronchitis: p = 0.01; and in chronic bronchitis: p = 0.12.
cTrend test from no chronic bronchitis, probable chronic bronchitis, to chronic bronchitis in secondhand smokers: p =0 . 0 1( p = 0.05 in 1<SHS<32 years and p =
0.01 in SHS ≧ 32 years); and in smoker: p < 0.01.
Table 3 Relationships between cigarette smoking and SHS exposure in lifetime status and the severity of COPD
according to GOLD criteria.
Variables No COPD
(n = 230)
Mild COPD (n = 129) Moderate COPD (n = 58)
N (%) N (%) AOR (95%CI)
a PAR (%) N (%) AOR (95%CI)
a PAR (%)
Cigarette smoking/SHS status
Non-smoker 90 (39.1) 32 (24.8) 1 9 (15.5) 1
Second-hand smoker 133 (57.8) 83 (64.3) 1.76 (1.06-2.93) 26.5 44 (75.9) 3.84 (1.72-8.60)
c 56.2
Smoker 7 (3.0) 14 (10.9) 7.01 (2.52-19.51) 8.9 5 (8.6) 6.49 (1.61-26.15)
c 7.3
Cigarette smoking and cumulative SHS exposure (year)
Non-smoker 90 (39.1) 32 (24.8) 1 9 (15.5) 1
Second-hand smoker
1 < SHS < 32 73 (31.7) 38 (29.5) 1.48 (0.82-2.68) 20 (34.5) 3.31 (1.36-8.06)
c
SHS ≥ 32 60 (26.1) 45 (34.9) 2.05 (1.16-3.64)
b 24 (41.4) 4.43 (1.85-10.60)
b,c
Smoker 7 (3.0) 14 (10.9) 7.04 (2.53-19.61) 5 (8.6) 6.51 (1.61-26.32)
aAOR: Adjusting for age, secondhand smoke status, height, education level, cooking status, burning incense and tea consumption.
bTrend test from Non-SHS, 1<SHS<32, to SHS ≧ 32 years in Mild COPD: p = 0.01; and in Moderate COPD: p < 0.01.
cTrend test from No COPD, Mild COPD, to Moderate COPD in second-hand smoker: p < 0.01 (p < 0.01 in 1<SHS<32 years and SHS ≧ 32 years); and in smoker: p <
0.01.
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married to non-smokers, but did not find a similar
increase in women whose spouses smoked > 1 pack/
day [24]. Simoni and his colleagues, performing a simi-
lar study, found female spouses of smokers to be at
2.24 times (95%CI: 1.40-3.58) more risk to have
obstructive lung disease than those married to non-
smokers. Unfortunately, this study population covered
asthma or emphysema disease and this might reflect
the complex nature of the disease [27]. In a longitudi-
nal study, Sandler and his colleagues followed 14,783
healthy subjects exposed to SHS for 12 years and
f o u n dt h a tt h ee s t i m a t e dr e l a t i v er i s k( R R )o fd e a t hf o r
emphysema or bronchitis was 5.65 (95% CI: 1.19-26.8);
this result may be confounded by the small number of
deaths (13) in that study [26].
A dose-response relationship was noted between dura-
tion of SHS exposure at home by the cut-point of 32
SHS exposure years and COPD severity based on spiro-
metry, although it was present based on the criteria of
physician diagnosis and crosschecked with ATS criteria.
The probable reason is: the category of disease pheno-
type by ATS criteria, which was subjective, was not as
accurate as by pulmonary function tests, which was
objective. One study reported that only those with long
duration of SHS exposure (42 years or more at home)
were at increased risk of COPD (AORs:1.55; 95%
CI:1.09-2.21) [17]. Thus, our findings add additional
information about the association of cumulative SHS
exposure with COPD risk in non-smokers.
Cotinine in urine is widely used as a biomarker of
SHS exposure in epidemiology studies [35]. Although
our study relied on self-reports of SHS exposure, we
measured urinary cotinine levels in a subset of study
subjects to verify the questionnaire data, as similarly
done with other studies [23,27,28]. We found the urin-
ary cotinine levels in smokers, second-hand smokers
and non-smokers to agree well with a report that urin-
ary excretion of the nicotine metabolites in smokers is
approximately one hundred times higher than that
observed in second-hand smokers and non-smokers
[36]. In our study, the more exposure to SHS our sec-
ond-hand smokers self-reported per day, the higher
their cotinine levels, confirming the validity of response
to the questionnaire item. This agreement has been
found by others [37-39]. Eisner and his colleagues
reported the first study indicating that the highest urine
cotinine tertile was associated with poorer COPD sever-
ity scores both in cross-sectional or 1-year follow-up
study [18], which adds substantive additional evidence
that SHS exposure is deleterious for patients with
COPD by objective measures of urinary cotinine levels.
What this study adds
PAR% has been used to judge priorities for public health
action [34,40]. Because there is a high prevalence of
cigarette smoking in Caucasian men and women, several
studies in those countries have considered the PAR%
with regard to smoking and COPD [8,41,42]. The smok-
ing attributable fraction of COPD mortality in the United
Table 4 Predictors of absolute FEV1 level and FEV1/FVC (%): in a multiple linear regression model
a
Variables Adjusted analysis Adjusted analysis
N FEV1 (L)
(mean ± SD)
b(SE) p-value FEV1/FVC (%)
(mean ± SD)
b(SE) p-value
Age 417 1.56 ± 0.46 -0.022 (0.002) <0.01 81.10 ± 15.59 -0.134 (0.090) 0.14
Height 417 0.021 (0.004) <0.01 0.421 (0.146) <0.01
Education levels
≥junior high school 71 1.80 ± 0.41 1 80.94 ± 14.79 1
primary school 225 1.59 ± 0.46 -0.044 (0.053) 0.41 81.04 ± 15.79 1.820 (2.142) 0.4
illiteracy 121 1.37 ± 0.40 -0.079 (0.063) 0.21 81.32 ± 15.79 3.068 (2.554) 0.23
Cigarette smoking and cumulative SHS exposure year
Non-smoker 131 1.60 ± 0.41 1 86.83 ± 12.57 1
Second-hand smoker
1 < SHS < 32 131 1.63 ± 0.47 -0.095 (0.046) 0.04 80.70 ± 14.75 -5.807 (1.900) <0.01
SHS ≥ 32 129 1.51 ± 0.47 -0.113 (0.046) 0.01 77.07 ± 16.86 -9.436 (1.869) <0.01
Smoker 26 1.29 ± 0.50 -0.246 (0.079) <0.01 74.24 ± 18.18 -11.592 (3.226) <0.01
Burning incense
no 182 1.63 ± 0.47 1 81.70 ± 15.57 1
yes 235 1.51 ± 0.44 -0.091 (0.037) 0.02 80.64 ± 15.62 -1.654 (1.523) 0.28
Cooking status
no 17 1.56 ± 0.48 1 83.80 ± 15.69 1
yes 400 1.56 ± 0.46 0.012 (0.094) 0.9 80.99 ± 15.59 -2.243 (3.805) 0.56
aThree subjects did not have complete lung function test information.
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Page 7 of 10States has been reported to be 69.4% for women. In that
same time period, smoking was prevalent in 28.3-31.6%
of the women and 31.8-40.6% of the men in the United
States [8]. In Taiwan, the gap in smoking prevalence
between women and men (3-4% vs. 55-60%) is much
wider, so using PAR% would be helpful to study the con-
tribution of SHS exposure to the risk of chronic bronchi-
tis. Eisner and his colleagues reported that the PAR% was
eleven percent for the highest quartile of home SHS
exposure and seven percent for work exposure, though it
is not known how they calculated these percentages [17].
The results of the above studies are, except for age,
based on a single risk factor without regard to other fac-
tors [27,41]. Using a multivariate model to calculate
summary PAR% [34], we found although the AORs for
chronic bronchitis for smokers is high, the prevalence of
cigarette smoking among women is low. This made the
PAR% for chronic bronchitis caused by cigarette smok-
ing to be quite low (23.2%) (Table 2). In contrast, we
found the AORs for chronic bronchitis showed that
women exposed to SHS were 3.65 times more likely
than those not exposed to SHS to have chronic bronchi-
tis. This risk combined with a very high prevalence rate
for exposure to SHS yielded a 47.3 PAR%, higher than
the report from Simoni and his colleagues (adjusted
PAR% = 12%) [27], making SHS a more important pub-
lic health issue in non-smoking women. Similar results
of PAR% occurred when we analyzed the SHS-attributa-
ble fraction of COPD severity (Table 3). The above
results suggest that SHS exposure may be the underly-
ing reason for the high prevalence of chronic bronchitis
among non-smoking Taiwanese women. As shown in
our female population, who smoke relatively rarely
(3-4%), but live with high male smoking prevalence
(55-62%) [9], this provides a good opportunity to add
information on poorly investigated respiratory disease
effects of lifetime SHS exposure in Taiwanese non-
smoking women.
Limitations of this study
Our study has some limitations. First, the prevalence rate
for chronic bronchitis in women was relatively low, prob-
ably because we required that each woman must be diag-
nosed as having chronic bronchitis at least twice that
year in order to be included as an experimental case
from our national claims data. This would cause an
underestimation. Second, we have only randomly selected
about 17% study cases for interview to date and the
response rates in the groups of study cases and controls
were about sixty-seven percent, which was not very high.
This might increase the likelihood of selection bias; how-
ever, the age of responders and non-responders was com-
parable, and unlikely to bias our results. In addition,
subjects were blinded to the purpose of our study, so
their concern about lung function with their exposure or
disease outcome should not cause bias in our study.
Third, in this study, there was probably some recall bias
regarding estimates of lifetime exposure status. Still, the
misclassification of exposure is likely to be random,
which would have null effect on our results. Regardless,
we were still able to find significant risk, suggesting that
this bias might not exert much influence on our results.
Conclusion
In conclusion, we found a dose-response trend on the
effect of lifetime exposure to SHS and risk for chronic
bronchitis, with SHS exposure accounting for 47.3% of
the attributable risks of having chronic bronchitis. Our
findings add additional evidence to the growing body of
knowledge supporting the great need for health policies
to ensure that a smoke-free environment is created and
maintained for the public to decrease the risk of adverse
health consequences by non-smokers exposed to SHS.
Additional file 1: Appendix 1. The flow-chart of the study design.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2458-10-
44-S1.DOC]
Additional file 2: Appendix 2. The distribution of natural log-
transformed urine cotinine/creatinine levels among the groups of
smokers (n = 4), second-hand smokers (n = 23), and non-smokers (n =
44).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2458-10-
44-S2.DOC]
Additional file 3: Appendix 3. Summary of epidemiologic studies on
the relationship between SHS exposure and the risk of chronic
obstructive pulmonary disease (COPD) among women.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2458-10-
44-S3.DOC]
Acknowledgements
This research was supported by grants from the National Science Council,
Taiwan (NSC 95-2314-B-037-109-MY3), from the Center of Excellence for
Environmental Medicine, Kaohsiung Medical University, Taiwan (KMU-EM-97-
1.2a), from Kaohsiung Medical University Hospital (KMUH 98-8R05), and from
the Kaohsiung Armed Forces General Hospital, Taiwan (9703). We thank
Professor Tzy-Jyun Yao and research assistant Jih-Shin Liu at the National
Health Research Institute for helping us search Taiwan’s National Health
Insurance Bureau database and find potential study subjects, as well as all
the interviewers who worked very hard as they conducted personal
interviews in the homes of our study participants.
Author details
1Graduate Institute of Occupational Safety and Health, Kaohsiung Medical
University, Kaohsiung, Taiwan.
2Chest Medicine, Medical Department,
Kaohsiung Armed Forces General Hospital, Kaohsiung, Taiwan.
3Division of
Pulmonology, Department of Internal Medicine, Kaohsiung Medical
University, Kaohsiung, Taiwan.
4Division of Environmental Health and
Occupational Medicine, National Health Research Institutes, Miaoli, Taiwan.
5School of Public Health, Kaohsiung Medical University, Kaohsiung, Taiwan.
6Department of Family Medicine, Kaohsiung Medical University Hospital,
Kaohsiung, Taiwan.
7Department of Environmental Health, Harvard School of
Public Health, Boston, MA, USA.
8Department of Occupational Medicine,
Wu et al. BMC Public Health 2010, 10:44
http://www.biomedcentral.com/1471-2458/10/44
Page 8 of 10Kaohsiung Municipal Hsiao-Kang Hospital, Kaohsiung, Taiwan.
9Center of
Excellence for Environmental Medicine, Kaohsiung Medical University,
Kaohsiung, Taiwan.
Authors’ contributions
WC was responsible for data collection, statistical analysis, data
interpretation, and wrote the first draft of the manuscript. FN, CI, HJ and CS
contributed the clinical data collection, data interpretation and critical
revision of the manuscript. WK was responsible for urinary cotinine and
creatinine measurement for quality assurance and critical revision of the
manuscript. LC contributed the statistical analysis, data interpretation and
critical revision of the manuscript. HC and LC co-wrote the study design,
and contributed to the statistical analysis, data interpretation and critical
revision of the manuscript. CD was responsible for study supervision and
critical revision of the manuscript. WM created the original study design, and
was responsible for protocol development, survey design, data interpretation
and critical revision of the manuscript. All authors read and approved the
final version.
Competing interests
The authors declare that they have no competing interests.
Received: 6 November 2009
Accepted: 28 January 2010 Published: 28 January 2010
References
1. American Thoracic Society: Standards for the diagnosis and care of
patients with chronic obstructive pulmonary disease. Am J Respir Crit
Care Med 1995, 152(5 Pt 2):S77-S83.
2. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM: Global
burden of COPD: systematic review and meta-analysis. Eur Respir J 2006,
28(3):523-532.
3. Murray CJ, Lopez AD: Alternative projections of mortality and disability
by cause 1990-2020: Global Burden of Disease Study. Lancet 1997,
349(9064):1498-1504.
4. Asia Pacific COPD Roundtable Group: Global initiative for chronic
obstructive lung disease strategy for the diagnosis, management and
prevention of chronic obstructive pulmonary disease: an Asia-Pacific
perspective. Respirology 2005, 10(1):9-17.
5. Department of Health: Health Statistics. Vital statistics Taipei, Taiwan:
Department of Health, Executive Yuan, ROCII:2000-2008.
6. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y,
Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J: Global strategy for
the diagnosis, management, and prevention of chronic obstructive
pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med
2007, 176(6):532-555.
7. Mannino DM, Buist AS: Global burden of COPD: risk factors, prevalence,
and future trends. Lancet 2007, 370(9589):765-773.
8. Davis RM, Novotny TE: The epidemiology of cigarette smoking and its
impact on chronic obstructive pulmonary disease. Am Rev Respir Dis
1989, 140(3 Pt 2):S82-S84.
9. Bureau of Tobacco and Alcohol Monopoly: Annual Report of Tobacco,
Alcohol Consumption Investigation in Taiwan Area Taipei, Taiwan: Bureau of
Tobacco and Alcohol Monopoly, Taiwan Provincial Government1974-1996.
10. Lee CH, Ko YC, Goggins W, Huang JJ, Huang MS, Kao EL, Wang HZ:
Lifetime environmental exposure to tobacco smoke and primary lung
cancer of non-smoking Taiwanese women. Int J Epidemiol 2000,
29(2):224-231.
11. Bureau of Health Promotion: Taiwan Tobacco Control Annual Report Taipei,
Taiwan: Bureau of Health Promotion, Department of Health, ROC 2009.
12. Liu BQ, Peto R, Chen ZM, Boreham J, Wu YP, Li JY, Campbell TC, Chen JS:
Emerging tobacco hazards in China: 1. Retrospective proportional
mortality study of one million deaths. BMJ 1998, 317(7170):1411-1422.
13. Daisey JM: Tracers for assessing exposure to environmental tobacco
smoke: what are they tracing?. Environ Health Perspect 1999, 107(Suppl
2):319-327.
14. Jaakkola MS, Jaakkola JJ: Effects of environmental tobacco smoke on the
respiratory health of adults. Scand J Work Environ Health 2002, 28(Suppl
2):52-70.
15. Witschi H, Joad JP, Pinkerton KE: The toxicology of environmental tobacco
smoke. Annu Rev Pharmacol Toxicol 1997, 37:29-52.
16. Woodruff PG, Ellwanger A, Solon M, Cambier CJ, Pinkerton KE, Koth LL:
Alveolar macrophage recruitment and activation by chronic secondhand
smoke exposure in mice. COPD 2009, 6(2):86-94.
17. Eisner MD, Balmes J, Katz PP, Trupin L, Yelin EH, Blanc PD: Lifetime
environmental tobacco smoke exposure and the risk of chronic
obstructive pulmonary disease. Environ Health 2005, 4(1):7-15.
18. Eisner MD, Balmes J, Yelin EH, Katz PP, Hammond SK, Benowitz N, Blanc PD:
Directly measured secondhand smoke exposure and COPD health
outcomes. BMC Pulm Med 2006, 6:12-22.
19. Eisner MD, Iribarren C, Yelin EH, Sidney S, Katz PP, Sanchez G, Blanc PD: The
impact of SHS exposure on health status and exacerbations among
patients with COPD. Int J Chron Obstruct Pulmon Dis 2009, 4(1):169-176.
20. Radon K, Busching K, Heinrich J, Wichmann HE, Jorres RA, Magnussen H,
Nowak D: Passive smoking exposure: a risk factor for chronic bronchitis
and asthma in adults?. Chest 2002, 122(3):1086-1090.
21. Yin P, Jiang CQ, Cheng KK, Lam TH, Lam KH, Miller MR, Zhang WS,
Thomas GN, Adab P: Passive smoking exposure and risk of COPD among
adults in China: the Guangzhou Biobank Cohort Study. Lancet 2007,
370(9589):751-757.
22. Enstrom JE, Kabat GC: Environmental tobacco smoke and tobacco-related
mortality in a prospective study of Californians, 1960-98. BMJ 2003,
326(7398):1057-1067.
23. Forastiere F, Mallone S, Lo Presti E, Baldacci S, Pistelli F, Simnoi M,
Scalera A, Pedreschi M, Pistelli R, Cor b oG ,R a p i t iE ,A g a b i t iN ,F a r c h iS ,
Basso S, Chiaffi L, Matteelli G, Di Pede F, Carrozzi L, Viegi G:
Characteristics of nonsmoking women exposed to spouses who
smoke: epidemiologic study on environment and health in women
from four Italian areas. Environ Health Perspect 2000,
108(12):1171-1177.
24. Kalandidi A, Trichopoulos D, Hatzakis A, Tzannes S, Saracci R: Passive
smoking and chronic obstructive lung disease. Lancet 1987,
2(8571):1325-1326.
25. Lee PN, Chamberlain J, Alderson MR: Relationship of passive smoking to
risk of lung cancer and other smoking-associated diseases. Br J Cancer
1986, 54(1):97-105.
26. Sandler DP, Comstock GW, Helsing KJ, Shore DL: Deaths from all causes in
non-smokers who lived with smokers. Am J Public Health 1989,
79(2):163-167.
27. Simoni M, Baldacci S, Puntoni R, Pistelli F, Farchi S, Lo Presti E, Pistelli R,
Corbo G, Aqabiti N, Basso S, Matteelli G, Di Pede F, Carrozzi L, Forastiere F,
Viegi G: Respiratory symptoms/diseases and environmental tobacco
smoke (ETS) in never smoker Italian women. Respir Med 2007,
101(3):531-538.
28. Vineis P, Airoldi L, Veglia P, Olgiati L, Pastorelli R, Autrup H, Dunning A,
Garte S, Gormally E, Hainaut P, Malaveille C, Matullo G, Peluso M, Overvad K,
Tjonneland A, Clavel-Chapelon F, Boeing H, Krogh V, Palli D, Panico S,
Tumino R, Bueno-De-Mesquita B, Peeters P, Berqulund G, Hallmans G,
Saracci R, Riboli E: Environmental tobacco smoke and risk of respiratory
cancer and chronic obstructive pulmonary disease in former smokers
and never smokers in the EPIC prospective study. BMJ 2005,
330(7486):277-282.
29. Wang SL, Chiou JM, Chen CJ, Tseng CH, Chou WL, Wang CC, Wu TN,
Chang LW: Prevalence of non-insulin-dependent diabetes mellitus and
related vascular diseases in southwestern arseniasis-endemic and
nonendemic areas in Taiwan. Environ Health Perspect 2003,
111(2):155-159.
30. Bernert JT Jr, Turner WE, Pirkle JL, Sosnoff CS, Akins JR, Waldrep MK, Ann Q,
Covey TR, Whitfield WE, Gunter EW, Miller BB, Patterson DG Jr, Needham LL,
Hannon WH, Sampson EJ: Development and validation of sensitive
method for determination of serum cotinine in smokers and
nonsmokers by liquid chromatography/atmospheric pressure ionization
tandem mass spectrometry. Clin Chem 1997, 43(12):2281-2291.
31. Keskinen H, Piirila P, Nordman H, Nurminen M: Pocked-sized spirometer
for monitoring bronchial challenge procedures. Clin Physiol 1996,
16(6):633-643.
32. Baldwin ED, Cournand A, Richards DW Jr: Pulmonary insufficiency;
physiological classification, clinical methods of analysis, standard values
in normal subjects. Medicine 1948, 27(3):243-278.
33. Berglund E, Birath G, Bjure J, Grimby G, Kjellmer I, Sandqvist L, Soderholm B:
Spirometric studies in normal subjects. I. Forced expirograms in subjects
between 7 and 70 years of age. Acta Med Scand 1963, 173:185-192.
Wu et al. BMC Public Health 2010, 10:44
http://www.biomedcentral.com/1471-2458/10/44
Page 9 of 1034. Bruzzi P, Green SB, Byar DP, Brinton LA, Schairer C: Estimating the
population attributable risk for multiple risk factors using case-control
data. Am J Epidemiol 1985, 122(5):904-914.
35. Benowitz NL: Cotinine as a biomarker of environmental tobacco smoke
exposure. Epidemiol Rev 1996, 18(2):188-204.
36. Hansen AM, Garde AH, Christensen JM, Eller N, Knudsen LE, Heinrich-
Ramm R: Reference interval and subject variation in excretion of urinary
metabolites of nicotine from non-smoking healthy subjects in Denmark.
Clin Chim Acta 2001, 304(1-2):125-132.
37. Etter JF, Vu Duc T, Perneger TV: Saliva cotinine levels in smokers and
nonsmokers. Am J Epidemiol 2000, 151(3):251-258.
38. Klebanoff MA, Levine RJ, Clemens JD, DerSimonian R, Wilkins DG: Serum
cotinine concentration and self-reported smoking during pregnancy. Am
J Epidemiol 1998, 148(3):259-262.
39. Lewis SJ, Cherry NM, McL Niven R, Barber PV, Wilde K, Povey AC: Cotinine
levels and self-reported smoking status in patients attending a
bronchoscopy clinic. Biomarkers 2003, 8(3-4):218-228.
40. Northridge ME: Public health methods–attributable risk as a link between
causality and public health action. Am J Public Health 1995,
85(9):1202-1204.
41. Lindberg A, Bjerg-Backlund A, Ronmark E, Larsson LG, Lundback B:
Prevalence and underdiagnosis of COPD by disease severity and the
attributable fraction of smoking Report from the Obstructive Lung
Disease in Northern Sweden Studies. Respir Med 2006, 100(2):264-272.
42. Wilson D, Adams R, Appleton S, Ruffin R: Difficulties identifying and
targeting COPD and population-attributable risk of smoking for COPD: a
population study. Chest 2005, 128(4):2035-2042.
Pre-publication history
The pre-publication history for this paper can be accessed here:http://www.
biomedcentral.com/1471-2458/10/44/prepub
doi:10.1186/1471-2458-10-44
Cite this article as: Wu et al.: Second-hand smoke and chronic
bronchitis in Taiwanese women: a health-care based study. BMC Public
Health 2010 10:44.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Wu et al. BMC Public Health 2010, 10:44
http://www.biomedcentral.com/1471-2458/10/44
Page 10 of 10